Cases of ICP were reported in pregnant patients receiving azathioprine or 6-mercaptopurine to treat inflammatory bowel disease or systemic lupus erythematosus.
Gastrohepatic Disorders
— DRUG MONOGRAPHS BY SUBSECTION —
News and Features
Adjusted odds ratios of 1.70, 1.40, and 1.30 seen for proton pump inhibitors, H2 receptor antagonists, and generic antacids, respectively.
The approval was based on data from the phase 3 VISIBLE 2 trial.
Findings seen in children with pancreatic sufficient acute recurrent pancreatitis or chronic pancreatitis.
Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network.
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.
The YELLOWSTONE clinical development program includes two 12-week double-blind, placebo-controlled induction studies.
Participants were asked to rank products in 132 OTC categories.
Medical therapy suggested over early endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis without cholangitis.
Semaglutide linked to declines in intrahepatic triglycerides for people with HIV with metabolic-associated steatotic liver disease
The approval was based on data from the pivotal phase 3 MAESTRO-NASH study, which included patients with biopsy-proven NASH and fibrosis who were on stable doses of medications for diabetes, dyslipidemia, and hypertension.
The approval was based on data from the phase 3 MARCH-PFIC trial.
GLP-1 RA use associated with higher prevalence of residual gastric content in participants undergoing elective procedure under anesthesia.
The table below is a review of notable updates that occurred in February 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
One-year outcomes better with early combined infliximab + immunomodulator vs. accelerated step-up treatment.
The double-blind, placebo-controlled STARS trial assessed the safety and efficacy of apraglutide, a long-acting synthetic glucagon-like peptide-2 analog, in adult patients with SBS-IF.
ColoTest is designed to detect blood in stool, which may be an early indication for colorectal cancer, diverticulitis, gastrointestinal disorders, colitis or polyps.
Simlandi is an interchangeable biosimilar and can be substituted for the reference product without requiring a prescription change.
The product is supplied in a 30g tube and will be available soon.
The application is supported by data from the multicohort phase 2 KRYSTAL-1 study, which evaluated adagrasib in heavily pretreated patients with KRASG12C-mutated advanced CRC.
- Loading...
